Quantum Biopharma (QNTM) Income from Non-Controlling Interests (2020 - 2026)

Quantum Biopharma has reported Income from Non-Controlling Interests for 7 years, with the latest figure at -$13.8 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 57.37% year-over-year to -$13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.5 million (up 44.48% YoY) and the FY2025 annual result came in at -$27.0 million, down 80.73% from the prior year.
• Income from Non-Controlling Interests retreated to -$13.8 million in Q1 2026 per QNTM's latest filing, from -$3.7 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $5.9 million in Q1 2022 and troughed at -$24.4 million in Q4 2024.
• A 5-year average of -$6.7 million and a median of -$4.0 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests tumbled 5526.7% in 2024, then surged 218.24% in 2025.
• Over 5 years, Income from Non-Controlling Interests stood at $5.9 million in 2022, then slumped by 407.51% to -$18.2 million in 2023, then plunged by 34.23% to -$24.4 million in 2024, then soared by 84.81% to -$3.7 million in 2025, then tumbled by 271.41% to -$13.8 million in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$13.8 million, -$3.7 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.